# US 2026/0216219 A1 · Modulator for promoting binding of butyrophilin 3a1/2a1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216219 A1
- Document ID: US20260216219A1
- Status: Published application
- Kind: A1
- Application number: 19/145,927
- Filed: 2024-01-05
- Published: 2026-07-30
- Earliest claimed: 2023-01-06
- Assignees: Unicet Biotech Co. LLC.
- Applicants: Unicet Biotech Co., LLC
- Inventors: Weiwei Ma; Yonghua XIE; Yinqiang SUI; Hui ZHANG; Rui HAO
- Web page: https://patentgrep.com/patent/US20260216219A1

## CPC

- A61K 31/665: having oxygen as a ring hetero atom, e.g. fosfomycin
- A61P 37/04: Immunostimulants
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/664: Amides of phosphorus acids
- A61P 35/00: Antineoplastic agents
- C07F 9/242: {of hydroxyaryl compounds}
- C07F 9/4449: {Esters with hydroxyaryl compounds}
- C07F 9/65515: {the oxygen atom being part of a five-membered ring}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A compound of formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, which can promote binding of butyrophilin 3A1/2A1, wherein the definitions of groups are as detailed in the description and the claims. Also involved are a pharmaceutical composition containing the compound of formula (I) and use thereof in clinical treatment.

## Claims

### Claim 1

A compound of formula (X), or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof:
wherein,
ring A is C6-10 aryl or 5- to 10-membered heteroaryl;
Ra is selected from
X is O or CRR′;
Y is O, NH or CH2;
Z is O or NH;
R1 is selected from H, F, Cl, CN, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl, which are optionally substituted with 1-9 substituents independently selected from halogen, CN, OH and NH2;
R2 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkylene-C3-12 cycloalkyl, C0-6 alkylene-4- to 12-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 12-membered heteroaryl;
R3 is selected from H, C1-4 alkyl and C1-4 haloalkyl;
R4 is selected from H, C1-4 alkyl, C1-4 haloalkyl, —C(O)R″, —C(O)OR″, —C(O)NR″R″, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
or R3, R4 and the nitrogen atom to which they are attached are taken together to form a 4- to 7-membered heterocyclyl;
R5 is selected from —(CH2CH2O)nCH3, C1-10 alkyl, C1-10 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
R6 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl;
wherein,
R and R′ are independently selected from H and halogen;
R″ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
n=1, 2, 3, 4, 5, or 6.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein the compound has the formula (I):
wherein,
ring A is C6-10 aryl or 5- to 10-membered heteroaryl;
Ra is selected from
X is O or CRR′;
Y is O, NH or CH2;
R1 is selected from H, F, Cl, CN, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl, which are optionally substituted with 1-9 substituents independently selected from halogen, CN, OH and NH2;
R2 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-4- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
R3 is selected from H, C1-4 alkyl and C1-4 haloalkyl;
R4 is selected from H, C1-4 alkyl, C1-4 haloalkyl, —C(O)R″, —C(O)OR″, —C(O)NR″R″, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
or R3, R4 and the nitrogen atom to which they are attached are taken together to form a 4- to 7-membered heterocyclyl;
R5 is selected from —(CH2CH2O)nCH3, C1-10 alkyl, C1-10 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
R6 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl and C2-6 alkynyl;
wherein,
R and R′ are independently selected from H and halogen;
R″ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
n=1, 2, 3, 4, 5, or 6.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein ring A is phenyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein Ra is selected from
alternatively, Ra is selected from

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein X is CRR′, alternatively CH2 or CF2, and still alternatively CH2.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein Y is O.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R1 is selected from H, F, Cl, CN and C1-4 alkyl, said C1-4 alkyl is optionally substituted with 1-6 substituents independently selected from halogen and OH; alternatively, R1 is selected from H, F, Cl, CN and C1-2 alkyl, said C1-2 alkyl is optionally substituted with 1-5 substituents independently selected from halogen and OH; alternatively, R1 is selected from H, F, Cl, CN, CH3, CF3, CH2CH3 and CH2OH, and still alternatively CH3, CF3 and CH2OH, and still alternatively CH3.

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R2 is C1-6 alkyl, C3-7 cycloalkyl or 3- to 7-membered heterocyclyl, alternatively R2 is selected from isopropyl, cyclopentyl, 2-ethylbutyl and tetrahydropyranyl, and still alternatively R2 is selected from cyclopentyl and isopropyl.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R3 is H.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R4 is selected from —C(O)R″ and —C(O)OR″, alternatively —C(O)OR″.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R5 is C1-6 alkyl, C3-7 cycloalkyl or 3- to 7-membered heterocyclyl, alternatively R5 is selected from isopropyl, cyclopentyl and tetrahydrofuranyl.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R6 is C1-6 alkyl, alternatively methyl or isopropyl, and still alternatively methyl.

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein R″ is C1-6 alkylene-C6-10 aryl, alternatively benzyl.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, having the following general formula (II):
wherein,
Z1 is N or CRa1;
Z2 is N or CRa2;
Z3 is N or CRa3;
Z4 is N or CH;
Z5 is N or CH;
one of Ra1, Ra2 and Ra3 is selected from
and the others are H;
other groups are as defined in claim 1.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, having the following general formula (III):
wherein,
X is O or CRR′;
Y is O, NH or CH2;
R1 is selected from H, F, Cl, CN, C1-4 alkyl, C2-4 alkenyl and C2-4 alkynyl, which are optionally substituted with 1-9 substituents independently selected from halogen, CN, OH and NH2;
R2 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl and 3- to 7-membered heterocyclyl;
R3 is selected from H, C1-4 alkyl and C1-4 haloalkyl;
R4 is selected from H, C1-4 alkyl, C1-4 haloalkyl, —C(O)R″, —C(O)OR″, —C(O)NR″R″, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
or R3, R4 and the nitrogen atom to which they are attached are taken together to form a 4- to 7-membered heterocyclyl;
R5 is selected from —(CH2CH2O)nCH3, C1-10 alkyl, C1-10 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkylene-C3-7 cycloalkyl, C0-6 alkylene-3- to 7-membered heterocyclyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
wherein,
R and R′ are independently selected from H and halogen;
R″ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl;
n=1, 2, 3, 4, 5, or 6;
optionally,
wherein:
X is CH2;
Y is O;
R1 is selected from H, F, Cl, CN and methyl, wherein the methyl is optionally substituted with 1-3 substituents independently selected from halogen, CN, OH and NH2, alternatively R1 is methyl;
R2 is selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl and 3- to 7-membered heterocyclyl, alternatively R2 is selected from cyclopentyl and isopropyl;
R3 is selected from H, C1-4 alkyl and C1-4 haloalkyl, alternatively H:
R4 is selected from —C(O)R″, —C(O)OR″ and C0-6 alkylene-C6-10 aryl, alternatively —C(O)OR″;
R5 is selected from C1-10 alkyl, C3-7 cycloalkyl and 3- to 7-membered heterocyclyl, alternatively R5 is selected from isopropyl, cyclopentyl and tetrahydrofuranyl;
wherein,
R″ is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C0-6 alkylene-C6-10 aryl and C0-6 alkylene-5- to 10-membered heteroaryl, alternatively benzyl.

### Claim 16

(canceled)

### Claim 17

A compound, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof, wherein the compound is selected from:

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A method of treating a proliferative disease in a subject, the method comprising administering to the subject a compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the proliferative disease is selected from cancer, cardiovascular disorders, infectious diseases, chronic inflammatory diseases, autoimmune disorders and other cell proliferative disorders; optionally, wherein the cancer is selected from solid tumors and hematological malignancies, such as breast cancer, neuroblastoma, malignant rhabdomyomas, well-differentiated and dedifferentiated liposarcoma, glioma, lung cancer, colorectal cancer, gastric cancer, gastrointestinal stromal tumor (GIST), hepatocellular carcinoma, prostate tumor, sarcoma, ovarian cancer, cervical cancer, pancreatic cancer, melanoma, thyroid cancer, bile duct cancer, endometrial cancer, renal cancer, mesothelioma, lymphoma, leukemia, non-Hodgkin's lymphoma, mantle cell lymphoma, anaplastic large cell lymphoma, acute myeloid leukemia (AML), and multiple myeloma; alternatively, wherein the proliferative disease is selected from multiple myeloma, non-Hodgkin's lymphoma, lung cancer, renal cancer and prostate cancer.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of promoting binding of butyrophilin 3A1/2A1 in a subject, the method comprising administering to the subject a compound of claim 1, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a solvate, a hydrate, a polymorph or an isotopic variant thereof.
